Sodium thiosulfate

Drug Profile

Sodium thiosulfate

Alternative Names: STS - Fennec

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Oregon Health & Science University
  • Developer Fennec Pharmaceuticals
  • Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Sensorineural hearing loss

Most Recent Events

  • 01 Dec 2016 Fennec Pharmaceuticals completes a phase III trial in Sensorineural hearing loss (Chemotherapy-induced, In children, Prevention) in USA and Canada (NCT00716976)
  • 14 Nov 2016 Fennec Pharmaceuticals plans a compassionate use programme for Sensorineural hearing loss
  • 24 Oct 2016 Interim efficacy and safety data from the SIOPEL 6 phase III trial in Sensorineural hearing loss released by Fennec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top